'For
the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Gland Pharma has increased 64.68% to Rs 1545.16 crore compared to quarter ended Dec 2022. Operating profit margin has declined from 30.86% to 23.06%, leading to 23.08% rise in operating profit to Rs 356.39 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 45.68% to 32.76%. Purchase of finished goods cost rose from 0.41% to 0.45%. Employee cost increased from 10.67% to 24.38%. Other expenses rose from 12.71% to 17.24%. Power and Oil fuel cost rose from 3.08% to 4.52%. Other income fell 39.21% to Rs 37.39 crore. PBIDT rose 12.16% to Rs 393.78 crore. Provision for interest rose 101.53% to Rs 5.28 crore.
PBDT rose 11.49% to Rs 388.5 crore. Provision for depreciation rose 180.09% to Rs 105.34 crore.
Pleaselogin & subscribe to view the full report.
More Reports
-
Stable performance on growth, asset quality and margins
-
Margins improve, VNB rises
-
Strong performance with improved combined ratio
-
Revenue up 29% YoY, Net Profit up 28.9% YoY in Q3FY2025
|
|